Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands
Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the…